NUVA Overzicht aandelen
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 1/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
NuVasive, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$39.75 |
| 52 Week Hoogtepunt | US$49.53 |
| 52 Week Laag | US$35.17 |
| Bèta | 1.07 |
| 11 maand verandering | -0.63% |
| 3 maanden verandering | 0.84% |
| 1 Jaar Verandering | -8.30% |
| 33 jaar verandering | -22.24% |
| 5 jaar verandering | -42.71% |
| Verandering sinds IPO | 248.68% |
Recent nieuws en updates
Recent updates
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Apr 18
What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?
Jan 24NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price
Dec 31Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Dec 05These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well
Nov 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Sep 22Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Sep 01NuVasive Likely Undervalued, But It's Hard To Find Catalysts
Aug 17Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Aug 11NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M
Aug 03NuVasive: Industry Tailwinds More Than Fairly Priced
Jun 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jun 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
May 11NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Apr 20At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?
Mar 30NuVasive's Turnaround Story Needs A Boost From Better Results
Mar 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
Dec 28Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?
Dec 02NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Nov 11NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate
Oct 21Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital
Sep 29At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?
Aug 18NuVasive Still Getting No Love With COVID-19 And Competitive Worries
Aug 12Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Jul 27Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?
Jun 17Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital
May 30Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All
May 12Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Mar 30Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?
Mar 09Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares
Feb 16
A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jan 26NuVasive stock gains on study results of its X360 surgery approach
Jan 06What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Jan 05Rendement voor aandeelhouders
| NUVA | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 1.5% | 0.2% | -1.2% |
| 1Y | -8.3% | 25.5% | 30.6% |
Rendement versus industrie: NUVA presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 25.5 % opleverde.
Rendement versus markt: NUVA presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.6 % opleverde.
Prijsvolatiliteit
| NUVA volatility | |
|---|---|
| NUVA Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: NUVA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van NUVA is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1997 | 3,000 | Chris Barry | www.nuvasive.com |
NuVasive, Inc. Samenvatting
| NUVA fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.08b |
| Inkomsten(TTM) | US$28.45m |
| Inkomsten(TTM) | US$1.23b |
73.3x
Koers/Winstverhouding1.7x
P/S-verhoudingIs NUVA overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| NUVA resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.23b |
| Kosten van inkomsten | US$347.50m |
| Brutowinst | US$878.73m |
| Overige uitgaven | US$850.28m |
| Inkomsten | US$28.45m |
Laatst gerapporteerde inkomsten
Jun 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.54 |
| Brutomarge | 71.66% |
| Nettowinstmarge | 2.32% |
| Schuld/Eigen Vermogen Verhouding | 89.1% |
Hoe presteerde NUVA op de lange termijn?
Bekijk historische prestaties en vergelijking